Anheuser-Busch stock appears to be heading towards a Death Cross, a bearish technical pattern where the 50-day simple moving average (SMA) is poised to cross below the 200-day SMA. This pattern often ...

Scholar Rock Holding (SRRK) has shown a staggering 335% jump in share price following the success of its spinal muscular atrophy (SMA) treatment drug, Apitegromab, in a phase 3 trial. The treatment ...

Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two ...

Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an ...